FAKHRAVAC

FAKHRAVAC
	A vial of FakhraVac
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	Fakhra, MIVAC
Routes of; administration	Intramuscular
Legal status
Legal status	Emergency use authorization: IRN;

FAKHRAVAC (Persian: واکسن فخرا) is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research,^[1] a subsidiary of Iran's Ministry of Defense. It is the third Iranian COVID-19 vaccine reaching clinical trials.^[1]^[2]^[3] It is currently in phase III.^[4]^[5] It received emergency use authorization in Iran on 9 September 2021.^[4]

The vaccine is named after the Iranian nuclear scientist Mohsen Fakhrizadeh.^[1] According to the Iranian authorities, he was working on a vaccine in response to the COVID-19 pandemic in Iran.^[1]^[6] Fakhrizadeh was assassinated in November 2020 in an attack Iran and US intelligence attributed to Israel.^[1]^[7]

Medical uses[edit]

It requires two doses given by intramuscular injection 3 weeks apart.^[5]

Pharmacology[edit]

FAKHRAVAC is an inactivated virus-based vaccine.^[3]

Manufacturing[edit]

In August 2021, production capacity of the vaccine was reported to be 1 million dose per month and was planned to be "multiplied in a few months ".^[4] In October 2021, the production was reported to be stopped amid Iran's growing vaccine imports.^[8] In January 2022, the Director General of Health of the Ministry of Defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the Iranian Ministry of Health.^[9]

Clinical trials[edit]

Clinical trials of FAKHRAVAC
Phase	Registration number	Start	Number of participants			Age of participants
Phase	Registration number	Start	Total	Vaccine	Control	Age of participants
I	IRCT20210206050259N1 Archived 28 April 2021 at the Wayback Machine	8 March 2021	135	96?	39? (placebo)	18–55 years
II	IRCT20210206050259N2 Archived 16 June 2021 at the Wayback Machine	8 June 2021	500	250	250 (placebo)	18–70 years
III	IRCT20210206050259N3 Archived 7 September 2021 at the Wayback Machine	29 August 2021	41,128	20,564	20,564 (Sinopharm BIBP vaccine)	>18 years

Authorizations[edit]

FAKHRAVAC received emergency use authorization in Iran on 9 September 2021.^[4] In October 2021, Iran's Food and Drug Administration was considering giving full authorization to the vaccine for third/booster dose.^[8]

References[edit]

^ Jump up to: ^a ^b ^c ^d ^e Motamedi M (16 March 2021). "Iran starts human trials of its third domestic COVID vaccine". Al Jazeera.
^ "Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 21 March 2021.
^ Jump up to: ^a ^b "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 15 June 2021.
^ Jump up to: ^a ^b ^c ^d "Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news". Tasnim News Agency. Retrieved 9 September 2021.
^ Jump up to: ^a ^b "IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial". en.irct.ir. Archived from the original on 7 September 2021. Retrieved 7 September 2021.
^ "Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister". Pars Today. 28 November 2020. Archived from the original on 5 December 2020. Retrieved 7 September 2021.
^ The Assassination of Fakhrizadeh: Considerations and Consequences
^ Jump up to: ^a ^b Sinaee, Maryam (19 October 2021). "Iran Defense Ministry's Covid Vaccine Production To Be Discontinued". Iran International. Retrieved 24 October 2021.
^ "تحویل نخستین محموله واکسن فخرا به وزارت بهداشت". YJC News. 19 January 2022.

Scholia has a profile for FAKHRAVAC (Q107366045).

[:0-1] Jump up to: ^a ^b ^c ^d ^e Motamedi M (16 March 2021). "Iran starts human trials of its third domestic COVID vaccine". Al Jazeera.

[:1-2] "Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 21 March 2021.

[:2-3] Jump up to: ^a ^b "Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. Retrieved 15 June 2021.

[:4-4] Jump up to: ^a ^b ^c ^d "Iran Authorizes Emergency Use of Third Homegrown Vaccine - Defense news". Tasnim News Agency. Retrieved 9 September 2021.

[:3-5] Jump up to: ^a ^b "IRCT | Comparison of the safety, efficacy and immunogenicity of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomised, non-inferiority clinical trial". en.irct.ir. Archived from the original on 7 September 2021. Retrieved 7 September 2021.

[6] "Research center run by Fakhrizadeh produced first COVID-19 test kits for Iranians: Defense minister". Pars Today. 28 November 2020. Archived from the original on 5 December 2020. Retrieved 7 September 2021.

[7] The Assassination of Fakhrizadeh: Considerations and Consequences

[:5-8] Jump up to: ^a ^b Sinaee, Maryam (19 October 2021). "Iran Defense Ministry's Covid Vaccine Production To Be Discontinued". Iran International. Retrieved 24 October 2021.

[9] "تحویل نخستین محموله واکسن فخرا به وزارت بهداشت". YJC News. 19 January 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]